Australia’s Circadian Takes Major Step In Marketing New Diagnostic
This article was originally published in PharmAsia News
Circadian Technologies, an Australian biotech, has signed the first of what it hopes to be several hospital systems to test and market its diagnostic capable of detecting the source of secondary cancers. CEO Robert Klupacs said the tie with Healthscope was the first of similar plans he hopes to announce over the coming year for Circadian's pipeline of products. He said he expects the cancer diagnostic, considered a breakthrough, to be commercialized within months. (Click here for more
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.